Lasting Effect Consumer Pharma

Company Overview

Snapshot

Founded in March 2020 by David Tavor, Igal Pikovsky, and Eli Heldman, Lasting Effect Consumer Pharma operates with 1–10 employees. The company has raised $1.85M across two funding rounds from three investors. In January 2023, the company received a grant from the Israel Innovation Authority.

Business overview

Lasting Effect Consumer Pharma develops pharmaceutical therapeutics utilizing a proprietary buccal extended-release drug delivery system. Their technology involves adhesive tablets designed to attach to the oral mucosa, facilitating continuous administration of active ingredients either topically or systemically, bypassing the digestive tract. This system addresses challenges such as dysphagia and administration compliance, serving markets with applications like saliva-stimulating treatments for dry mouth (xerostomia), anti-bacterial formulations for gingivitis, and a non-invasive solution for late-stage Parkinson’s disease to provide prolonged dopamine secretion. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Drug Delivery and Pharmaceuticals.

Company Intelligence Q&A

What is Lasting Effect Consumer Pharma's core technology?

Lasting Effect Consumer Pharma develops pharmaceutical therapeutics based on a proprietary buccal extended-release drug delivery system. This technology uses adhesive tablets that attach to the oral mucosa for continuous administration of active ingredients, either topically or systemically.

Which conditions does Lasting Effect Consumer Pharma's technology address?

The company's technology addresses challenges like swallowing difficulties and administration compliance. Key applications include saliva-stimulating treatments for dry mouth (xerostomia), anti-bacterial formulations for gingivitis, and a non-invasive solution for late-stage Parkinson’s disease.

When was Lasting Effect Consumer Pharma founded and by whom?

Lasting Effect Consumer Pharma was founded in March 2020 by David Tavor, Igal Pikovsky, and Eli Heldman.

What was a notable funding event for Lasting Effect Consumer Pharma?

In January 2023, Lasting Effect Consumer Pharma received a grant from the Israel Innovation Authority.

What is the current product stage for Lasting Effect Consumer Pharma?

Lasting Effect Consumer Pharma's products are currently in the Clinical Trial stage.